TabletsMRP Under Process
Official PMBI MRP is being updated for catalog code 2895.
Locate Jan Aushadhi KendraClinical Overview
Rabeprazole Sodium (20mg) and Mosapride Citrate (15mg) combines a rapid gastric acid suppressor with a selective 5-HT4 agonist prokinetic. It suppresses acid secretion while promoting gastric emptying and duodenal coordination, reducing acid contact time on esophageal mucosa. Indicated for GERD, reflux esophagitis, and chronic dyspepsia with dysmotility symptoms.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily, 30 minutes before breakfast with water. Swallow whole.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Diarrhea, loose stools, dry mouth, nausea, abdominal fullness. Rare/Severe: Hepatic dysfunction, elevated bilirubin/AST/ALT, eosinophilia.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in mechanical bowel obstruction or active gastrointestinal bleeding. Discontinue if signs of liver injury appear.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or gastrointestinal treatment recommendations. Always consult a registered gastroenterologist or qualified medical practitioner before initiating, altering, or discontinuing any gastrointestinal medication or digestive therapy.
Rabeprazole 20mg (Enteric Coated) + Domperidone 30mg (Sustained Release) Capsules
Rabeprazole Sodium (20mg enteric-coated) and Domperidone (10mg/30mg sustained-release) is a rapid-onset PPI and prokinetic combination. Rabeprazole has a higher pKa (~5.0) than other PPIs, allowing faster activation at higher pH and achieving rapid, potent inhibition of gastric H+/K+-ATPase pumps from the first dose. Domperidone provides dopamine D2 antagonism to enhance lower esophageal sphincter tone and accelerate gastric emptying. Indicated for erosive esophagitis, GERD, hypersecretory conditions, and dyspeptic symptom complexes (nausea, postprandial fullness, acid regurgitation).
Rabeprazole Gastro Resistant Tablets 20 mg
Rabeprazole Gastro-Resistant Tablets (20mg) is a second-generation proton pump inhibitor on the WHO Model List of Essential Medicines. It binds to gastric H+/K+-ATPase with high potency and dissociates more rapidly than first-generation PPIs, producing faster acid inhibition within hours of the first dose. Indicated for acute duodenal and gastric ulcers, gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome.
Rabeprazole 20mg + Domperidone 10mg Capsules
Rabeprazole Sodium (20mg enteric-coated) and Domperidone (10mg/30mg sustained-release) is a rapid-onset PPI and prokinetic combination. Rabeprazole has a higher pKa (~5.0) than other PPIs, allowing faster activation at higher pH and achieving rapid, potent inhibition of gastric H+/K+-ATPase pumps from the first dose. Domperidone provides dopamine D2 antagonism to enhance lower esophageal sphincter tone and accelerate gastric emptying. Indicated for erosive esophagitis, GERD, hypersecretory conditions, and dyspeptic symptom complexes (nausea, postprandial fullness, acid regurgitation).
Rabeprazole Sodium (Gastro-resistant) 20mg + Itopride Hydrochloride Prolonged release 150mg Capsules
Rabeprazole Sodium (20mg gastro-resistant) and Itopride Hydrochloride (150mg prolonged-release) combines an antisecretory PPI with an AChE-inhibiting and D2-antagonizing prokinetic. Itopride boosts acetylcholine availability to coordinate gastroduodenal contractions without prolonging cardiac QT intervals or elevating prolactin substantially. Indicated for GERD, reflux esophagitis, non-erosive reflux disease (NERD), and dysmotility-like functional dyspepsia.